GGrantIndex
← Search

CORE--DNA SEQUENCING AND ANALYSIS

$144,004P30FY2001CANIH

University Of Colorado Denver, Aurora CO

Investigators

Linked publications, trials & patents

Paper 39763739Paper 39737640Paper 39726772Paper 39711559Paper 39711135Paper 39684443Paper 39677775Paper 39677720Paper 39677022Paper 39671500Paper 39671496Paper 39630148Paper 39609428Paper 39604567Paper 39603869Paper 39574899Paper 39564580Paper 39554114Paper 39436696Paper 39400608Paper 39384405Paper 39342284Paper 39321266Paper 39311710Paper 39282307Paper 39266537Paper 39264810Paper 39215796Paper 39201277Paper 39191549Paper 39147413Paper 39139560Paper 39136655Paper 39120971Paper 39091762Trial NCT05073848Trial NCT05053737Trial NCT05006040Trial NCT04993859Trial NCT04988490Trial NCT04973007Trial NCT04963283Trial NCT04940468Trial NCT04925193Trial NCT04922112Trial NCT04916990Trial NCT04882111Trial NCT04866758Trial NCT04863092Trial NCT04634110Trial NCT04611022Trial NCT04565457Trial NCT04558138Trial NCT04544592Trial NCT04541407Trial NCT04535102Trial NCT04520867Trial NCT04486573Trial NCT04471363Trial NCT04408092Trial NCT04305366Trial NCT04300478Trial NCT04294693Trial NCT04208243Trial NCT04092803Trial NCT04091867Trial NCT04066218Trial NCT04042935Trial NCT04035408Trial NCT04028167Trial NCT04028063Trial NCT04001101Trial NCT03995082Trial NCT03976193Trial NCT03970226Trial NCT03958565Trial NCT03900793Trial NCT03891654Trial NCT03881098Trial NCT03781154Trial NCT03734653Trial NCT03617679Trial NCT03325634Trial NCT01886859Trial NCT01426334Trial NCT01232829Trial NCT00778167Patent 9434994Patent 8734778Patent 8715649Patent 8343502Patent 8337830Patent 8221763Patent 8153136Patent 8067559Patent 7910315Patent 7595060Patent 7563447Patent 7465454Patent 7083787

Abstract

Description: (Applicant's Description) The DNA Sequencing and Analysis Core is now in its 4th year of highly successful operation. Initiated as a fledging operation after the inception of the CU Cancer Center, the Core has grown remarkably with now 112 user groups, of which most are Cancer Center members. In addition to performing DNA sequencing reactions, Core services include preparation of various DNA templates and assisting customers with all technical aspects of DNA sequencing and analysis. The Core also prepares high-density filter arrays using customer prepared libraries. In addition to service functions, Core personnel reported improvements in basic DNA sequencing chemistry that permit longer, more accurate read-lengths and improved mutation detection. To facilitate research efforts of the CU Hereditary Cancer Clinic, the Core now offers screening for the BRCA1/2 185delAG, 5382insC and 6174delT mutations. Especially as a consequence of the Genome Project, the demand for DNA sequencing will continue to expand significantly. During the next period of support, the Core intends to continue its state-of-the-art services to Cancer Center members. Research-based mutation/polymorphism screening is also likely to expand. Over the past 4 years samples sequenced have increased from 1501 to 9410 (526%) and charge back fees have increased from $43,095 to $187,136 (334%). Because of the large increase we have been able to reduce fees which has led to continued increases in core usage. The core has been used by members of 9 of the 10 Cancer Center programs. The core will move to the Fitzsimons campus with the Cancer Center during the next grant cycle.

View original record on NIH RePORTER →